ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26may1804

Modulatory Effects of Pioglitazone on Lipid Metabolism in Obesity and Metabolic Syndrome: A Comprehensive Review

Priya Rani[1]; Ashish Kumar Mishra[2]

[1]Student Master of Pharmacy (Pharmacology), HRIP (HRIT University), Ghaziabad
[2]Associate Professor, Department of Pharmacology, HRIP (HRIT University), Ghaziabad

Publication Date: 2026/06/06

Abstract:

- ***Background:***
Pioglitazone, a thiazolidinedione (TZD) and selective peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, exerts pleiotropic effects on lipid homeostasis that extend well beyond its primary glucose-lowering activity. In the context of the global obesity epidemic and the rising prevalence of metabolic syndrome, understanding its lipid-modifying properties is of paramount clinical importance.

- ***Objective:***
This comprehensive review synthesizes current evidence on pioglitazone-mediated modulation of lipid metabolism in obese and metabolic syndrome patients, examining molecular mechanisms, clinical outcomes, hepatic effects, and safety considerations.

- ***Methods:***
A systematic search of PubMed, MEDLINE, Cochrane Library, and ClinicalTrials.gov databases was conducted. Studies published between 2000 and 2024 examining pioglitazone's lipid effects, mechanisms of action, and clinical outcomes were included.

- ***Results:***
Pioglitazone consistently elevates HDL-cholesterol (10–15%), reduces plasma triglycerides (10–30%), shifts LDL particle size from small-dense to large-buoyant subtypes, and significantly modulates adipokine profiles — notably increasing adiponectin by up to 111% in some trials. Its hepatic effects include reduction of de novo lipogenesis, redistribution of visceral to subcutaneous adipose tissue, and improvement of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) histology. Molecular mechanisms involve PPARγ-driven transcriptional regulation of SREBP-1c, LPL, ApoC-III, ApoA-I, CD36, FATP-1, and downstream signaling cascades including AMP-activated protein kinase (AMPK) and adiponectin receptors.

- ***Conclusions:***
Pioglitazone demonstrates a unique and favorable lipid-modifying profile in obesity and metabolic syndrome, positioning it as a valuable therapeutic option despite recognized adverse effects including weight gain, fluid retention, and bone fracture risk. Emerging deuterium-stabilized formulations (PXL065) may offer improved benefit-risk profiles.

How to Cite: Priya Rani; Ashish Kumar Mishra (2026) Modulatory Effects of Pioglitazone on Lipid Metabolism in Obesity and Metabolic Syndrome: A Comprehensive Review. *International Journal of Innovative Science and Research Technology*, 11(5), 3420-3430. https://doi.org/10.38124/ijisrt/26may1804

I. INTRODUCTION

Pioglitazone (5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy] phenyl]methyl]-2,4-thiazolidinedione) is a member of the thiazolidinedione (TZD) class of oral antidiabetic agents, first approved by the US FDA in 1999 for the treatment of type 2 diabetes mellitus (T2DM). As a highly selective, full agonist of peroxisome proliferator-activated receptor-gamma (PPARγ), pioglitazone exerts a broad spectrum of metabolic effects that extend considerably beyond glucose regulation, particularly with respect to lipid homeostasis.[1,2]

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26may1804

The global epidemic of obesity and metabolic syndrome has emerged as one of the most pressing public health challenges of the 21st century. The metabolic syndrome — characterized by central obesity, insulin resistance, dyslipidemia, elevated blood pressure, and a pro-inflammatory state — affects an estimated 25–35% of the adult population worldwide.[26,27,28] This cluster of metabolic derangements is intimately linked to accelerated atherosclerosis, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD), and cardiovascular mortality.[29,30]

Central to the pathophysiology of metabolic syndrome is an abnormality of lipid metabolism, manifesting as hypertriglyceridemia, reduced HDL-cholesterol, elevated small-dense LDL particles, and elevated circulating free fatty acids (FFA). These abnormalities are closely tied to adipose tissue dysfunction, impaired adipokine signaling, and hepatic lipotoxicity.[22,23,24] Pioglitazone, by virtue of its PPARγ-agonist activity, addresses each of these metabolic derangements at a molecular level, offering a pleiotropic lipid-modifying profile not replicated by any other class of antidiabetic agents.[1,15]

This comprehensive review synthesizes the current body of evidence on pioglitazone-mediated modulation of lipid metabolism in the context of obesity and metabolic syndrome. It examines molecular mechanisms, clinical trial data, hepatic effects, adipokine interactions, safety considerations, and emerging therapeutic developments, with an emphasis on the drug's unique position within the pharmacological armamentarium for metabolic disease.

II. PHARMACOLOGY AND MECHANISM OF ACTION

➢ *Chemical Structure and Pharmacokinetics*

Pioglitazone is a thiazolidinedione derivative with a molecular formula of $C_{19}H_{20}N_2O_3S$ and molecular weight of 356.44 g/mol. It is administered orally, with a bioavailability of approximately 80% following oral absorption. Peak plasma concentrations are achieved within 2 hours, and the drug undergoes extensive hepatic metabolism, primarily via CYP2C8 and CYP3A4, with a terminal half-life of 3–7 hours for the parent compound and 16–24 hours for active metabolites (M-III and M-IV).[1,14,15]

At steady-state, pioglitazone and its active metabolites achieve plasma concentrations sufficient for maximal PPARγ activation. Unlike rosiglitazone, which is primarily a PPARγ agonist, pioglitazone also demonstrates moderate PPARα agonist activity, a pharmacological distinction with significant implications for triglyceride metabolism and HDL elevation.[8,11,17]

➢ *PPARγ: The Central Molecular Target*

Peroxisome proliferator-activated receptor-gamma (PPARγ) is a ligand-activated nuclear transcription factor belonging to the nuclear receptor superfamily. Three PPARγ isoforms exist: PPARγ1 (ubiquitously expressed), PPARγ2 (predominantly adipose-specific), and PPARγ3.[13,19,20] PPARγ2 plays the most critical role in adipogenesis and lipid metabolism, and its expression is highest in white adipose tissue (WAT).[10,20]

Upon binding pioglitazone, PPARγ undergoes conformational changes, heterodimerizes with the retinoid X receptor (RXR), and binds to PPAR response elements (PPREs) in the promoter regions of target genes. This transcriptional cascade modulates the expression of hundreds of genes involved in lipid transport, adipogenesis, glucose metabolism, and inflammation.[13,16,17] Key target genes include those encoding adiponectin, lipoprotein lipase (LPL), CD36/FAT, FATP-1, FABP4/aP2, FSP27/CIDEC, and apolipoprotein C-III (ApoC-III).[8,9,11]

➢ *PPARα Co-Activation and its Lipid Consequences*

The moderate PPARα agonist activity of pioglitazone, distinguishing it from rosiglitazone, provides additional lipid-modifying benefits. PPARα activation promotes hepatic and mitochondrial fatty acid β-oxidation, reduces hepatic triglyceride synthesis, and modulates the expression of apolipoprotein A-I (ApoA-I) — the principal protein component of HDL particles.[11,17,41] This dual PPARα/γ activity is considered the primary mechanistic explanation for pioglitazone's more favorable triglyceride-lowering and HDL-raising profile compared to the purely PPARγ-selective rosiglitazone.[8,11]

III. EFFECTS ON TRIGLYCERIDE METABOLISM

➢ *Plasma Triglyceride Reduction*

Hypertriglyceridemia is a cardinal feature of the atherogenic dyslipidemia characteristic of metabolic syndrome. Multiple randomized controlled trials demonstrate that pioglitazone consistently reduces fasting plasma triglycerides by 10–30%, with the magnitude of reduction correlating with baseline triglyceride levels and the degree of insulin resistance.[2,3,7,9]

The primary mechanism of triglyceride lowering involves upregulation of lipoprotein lipase (LPL) in adipose tissue and skeletal muscle via PPARγ-mediated transcription. LPL is the rate-limiting enzyme for hydrolysis of triglyceride-rich lipoproteins (VLDL and chylomicrons). Simultaneously, pioglitazone decreases plasma levels of ApoC-III, an endogenous inhibitor of LPL, through PPARγ-mediated transcriptional repression.[11,15,38] The combined effect of LPL upregulation and ApoC-III suppression markedly enhances the clearance of VLDL-triglycerides from the circulation.[9,11]

➢ *Hepatic VLDL Production*

Beyond peripheral TG clearance, pioglitazone also reduces hepatic VLDL production. By redirecting free fatty acid (FFA) flux from the liver to adipose tissue — through enhanced FFA uptake via upregulated CD36 and FATP-1 in adipocytes, and suppression of adipose lipolysis via decreased hormone-sensitive lipase (HSL) activity — pioglitazone reduces the hepatic FFA substrate available for de novo lipogenesis and VLDL assembly.[8,22,23]

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26may1804

Gene expression profiling studies demonstrate that pioglitazone downregulates hepatic sterol regulatory element-binding protein-1c (SREBP-1c), the master transcriptional regulator of de novo lipogenesis, thereby reducing the expression of fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase-1 (SCD-1).[8,12,13] The net result is diminished hepatic triglyceride synthesis and reduced VLDL output.[6,8]

➢ *Free Fatty Acid Dynamics*

Elevated circulating FFA, a hallmark of insulin-resistant states, contributes to hepatic lipotoxicity, impaired insulin signaling, and atherogenic dyslipidemia. Pioglitazone reduces plasma FFA by 15–25% through multiple complementary mechanisms:[8,20,21]

- Suppression of adipose tissue lipolysis via downregulation of HSL and adipose triglyceride lipase (ATGL), reducing FFA release from visceral adipose stores;[8,10]
- Enhanced FFA re-esterification within adipose tissue, facilitated by PPARγ-driven upregulation of glycerol-3-phosphate acyltransferase (GPAT) and related enzymes;[20]
- Increased FFA uptake into adipocytes via upregulation of CD36, FATP-1, and LPL, promoting peripheral FFA sequestration rather than hepatic delivery;[8,9]
- Redistribution of fat storage from visceral (metabolically active) to subcutaneous (relatively inert) depots, reducing FFA flux from portal circulation to the liver.[15,18,64]

IV. EFFECTS ON HDL AND LDL METABOLISM

➢ *HDL-Cholesterol Elevation*

One of the most clinically significant lipid effects of pioglitazone is its consistent elevation of HDL-cholesterol (HDL-C). Clinical trials demonstrate HDL-C increases of 10–15% with pioglitazone treatment, a magnitude of HDL elevation comparable to that achieved with moderate-dose fibrates and exceeding that seen with most statin therapies.[4,7,9,11] In the landmark AHA MetSyn study, pioglitazone increased HDL-C by 15% at 6 weeks and 14% at 12 weeks compared to placebo in non-diabetic metabolic syndrome patients (P<0.001).[7]

The molecular basis for HDL elevation involves multiple mechanisms. First, pioglitazone directly enhances ApoA-I gene transcription in hepatocytes through PPAR response elements (PPREs) in the ApoA-I promoter, as demonstrated in HepG2 cell studies.[11,41] ApoA-I is the primary structural and functional protein of HDL particles, essential for reverse cholesterol transport (RCT) and macrophage cholesterol efflux. Second, the reduction in VLDL-TG levels decreases the exchange of triglycerides for cholesterol ester in HDL particles — a process mediated by cholesteryl ester transfer protein (CETP) — thereby preserving HDL-C content.[8,9]

The changes in HDL-C induced by pioglitazone have been strongly correlated with concomitant increases in adiponectin levels (r=0.34; P=0.01), suggesting that adiponectin signaling is an important intermediary in pioglitazone's HDL-raising mechanism.[7,32,33]

➢ *LDL Particle Size and Quality*

While pioglitazone has a relatively neutral to slightly positive effect on total LDL-cholesterol (0–10% change), its most clinically relevant LDL-related effect is the shift in LDL particle size from small, dense LDL (sdLDL) — the atherogenic subspecies — to large, buoyant LDL particles.[9,11] In the AHA MetSyn study, pioglitazone reduced small LDL particle number by 18% (P<0.001) compared to placebo, without significant changes in total LDL-C.[7]

Small-dense LDL particles are particularly atherogenic due to their prolonged residence time in plasma, greater susceptibility to oxidative modification, enhanced arterial wall penetration, and reduced affinity for the LDL receptor. The pioglitazone-mediated shift from sdLDL to large-buoyant LDL is mechanistically linked to the drug's triglyceride-lowering effect: reduced VLDL-TG levels decrease CETP-mediated TG-CE exchange, resulting in larger, cholesterol-enriched LDL particles.[8,9,11] This qualitative LDL improvement may represent a cardiovascular benefit distinct from LDL quantity-focused interventions.[3,26]

➢ *Reverse Cholesterol Transport (RCT)*

Emerging evidence suggests that pioglitazone enhances cholesterol efflux capacity — a key step in reverse cholesterol transport — through PPARγ-mediated upregulation of ABCA1 and ABCG1 transporters in macrophages.[26,48] In a 12-week pioglitazone study, cholesterol efflux capacity was significantly increased, an effect that may partially explain the drug's anti-atherogenic properties independent of changes in HDL-C concentration.[26]

Table 1 Key Clinical Trials Evaluating Pioglitazone's Effects on Lipid Metabolism

Study / Trial	Design	Population	Dose & Duration	Key Lipid Findings	Reference
PERISCOPE	RCT	T2DM + CAD (n=360)	45 mg, 18 months	↓TG, ↑HDL-C; slowed coronary atherosclerosis vs glimepiride	Nissen et al., 2008 [23]
PROactive	RCT	T2DM + CVD (n=5238)	45 mg, 34.5 months	↑HDL-C ~8%; ↓TG; reduced secondary MACE endpoint	Dormandy et al., 2005 [29]
PIVENS	RCT	Non-diabetic NASH (n=247)	30 mg, 96 weeks	↑Adiponectin; ↓hepatic steatosis; improved NAS score	Sanyal et al., 2010 [52]

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26may1804

IRIS	RCT	Insulin resistance + stroke (n=3876)	45 mg, 4.8 years	↓TG/HDL ratio; reduced stroke/MI recurrence vs placebo	Kernan et al., 2016 [38]
Cusi et al. NASH	RCT	T2DM + NASH (n=101)	45 mg, 18 months	↑HDL-C; ↓FFA; NASH resolution 51% vs 31% placebo	Cusi et al., 2016 [51]
EPICAMP	RCT	Non-diabetic MetSyn (n=104)	30 mg, 24 weeks	↑HDL-C; ↓CRP; improved endothelial markers	Tavintharan et al., 2013 [28]
TOSCA.IT subgroup	RCT	T2DM + NAFLD (n=195)	Low dose, 12 months	↓ADIPO-IR; ↓hepatic steatosis indices	Pappachan et al., 2022 [43]
AHA MetSyn Study	RCT	Non-diabetic MetSyn (n=60)	30 mg, 12 weeks	↑HDL-C +14%; ↓small LDL −18%; ↑Adiponectin +111%	Sidhu et al., 2006 [32]
DESTINY-1 (PXL065)	Phase II RCT	NASH (n=117)	7.5–22.5 mg, 36 weeks	↑Adiponectin +114%; ↓liver fat; improved fibrosis markers	Loomba et al., 2023 [58]
KKAy Mouse Study	Preclinical	Obese diabetic mice	30 days	↓Plasma TG; ↓FFA; ↑HDL-C; altered hepatic LDL-R/SR-BI expression	Peng et al., 2014 [8]

V. PIOGLITAZONE, ADIPOKINES, AND LIPID HOMEOSTASIS

➢ *Adiponectin: The Master Lipid Regulator*

Adiponectin is an adipocyte-derived hormone with potent insulin-sensitizing, anti-inflammatory, and anti-atherogenic properties. Paradoxically, adiponectin levels are markedly reduced in obesity and metabolic syndrome — conditions characterized by adipose tissue expansion — due to impaired adipocyte secretion related to adipose inflammation and oxidative stress.[32,33,37]

Pioglitazone is one of the most powerful pharmacological inducers of adiponectin secretion. Clinical studies demonstrate adiponectin increases of 50–111% with pioglitazone treatment, significantly exceeding the adiponectin-raising effect of metformin, statins, or DPP-4 inhibitors.[7,15,22,36] In the DESTINY-1 trial (PXL065, deuterated pioglitazone), adiponectin increased by 114% at the 22.5 mg dose compared to placebo (P<0.0001).[22]

The lipid metabolic consequences of pioglitazone-driven adiponectin elevation are multifaceted:[34,36]

- AMPK activation: Adiponectin activates AMP-activated protein kinase (AMPK) in liver and skeletal muscle, promoting fatty acid β-oxidation, inhibiting hepatic de novo lipogenesis, and reducing VLDL production.[34]
- PPARα co-activation: Adiponectin signaling enhances hepatic and muscle PPARα activity, further promoting mitochondrial fatty acid oxidation and reducing triglyceride accumulation.[17,34]
- Anti-inflammatory effects: Adiponectin suppresses pro-inflammatory cytokines (TNF-α, IL-6) that impair insulin signaling and promote hepatic lipogenesis, creating a positive feedback cycle.[46,47]
- HDL elevation: Adiponectin-AdipoR1 signaling in hepatocytes may enhance ApoA-I expression, contributing to HDL-C elevation.[11,33]

➢ *Resistin and Leptin*

Beyond adiponectin, pioglitazone modestly reduces plasma resistin levels (~10%), an adipokine associated with insulin resistance and pro-atherogenic lipid alterations.[7] The effects on leptin are variable; pioglitazone may reduce leptin in some contexts, consistent with its lipid-redistributing effects on adipose tissue architecture.[35] These adipokine changes contribute collectively to the improved lipid metabolic environment observed with pioglitazone therapy.

Table 2 Summary of Pioglitazone's Effects on Key Lipid Parameters

Lipid Parameter	Direction of Change	Magnitude	Primary Mechanism	Clinical Significance
Plasma Triglycerides (TG)	Decrease ↓	10–30%	↑LPL activity; ↓ApoC-III; ↑FFA re-esterification in adipose	Reduces atherogenic dyslipidemia; CVD risk ↓
HDL-Cholesterol	Increase ↑	10–15%	↑ApoA-I transcription via PPRE; ↑RCT	Antiatherogenic; major clinical benefit
LDL-Cholesterol (total)	Neutral/slight ↑	0–10%	↑LDL-R suppression in some contexts	LDL quality improved (large vs small-dense)
Small Dense LDL	Decrease ↓	Up to 18%	TG-rich VLDL remodeling; altered CETP activity	Critical for CVD risk reduction
Free Fatty Acids (FFA)	Decrease ↓	15–25%	↓HSL activity in WAT; ↑adipose FFA trapping	Reduces hepatic lipotoxicity and IR

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26may1804

VLDL Production	Decrease ↓	Variable	↓Hepatic de novo lipogenesis; ↓SREBP-1c	Reduces TG-rich lipoprotein burden
Adiponectin	Increase ↑	50–111%	PPARγ-driven adiponectin gene transcription	Improves insulin sensitivity; anti-inflammatory
Resistin	Decrease ↓	~10%	PPARγ-mediated suppression	Reduces inflammatory adipokine signaling
ApoC-III	Decrease ↓	Significant	PPARγ transcriptional repression	Key mechanism for TG lowering via LPL ↑
Hepatic TG (liver)	Variable / ↑ in some models	Context-dependent	PPARγ hyperactivation may ↑hepatic lipogenesis genes	Dual effect: beneficial in humans, complex in models

VI. HEPATIC LIPID METABOLISM AND NAFLD/NASH

➢ *Pathophysiology of Hepatic Lipid Accumulation*

The liver plays a central role in systemic lipid homeostasis, controlling biosynthesis, uptake, and secretion of triglycerides and cholesterol-rich lipoproteins. In obesity and metabolic syndrome, hepatic lipid accumulation — manifesting as NAFLD and its inflammatory form, NASH — is driven by excess portal FFA delivery, de novo lipogenesis, impaired β-oxidation, and reduced VLDL secretion.[23,24,42,50] Insulin resistance amplifies each of these pathways, and insulin-sensitizing therapy with pioglitazone may therefore provide hepatic benefit.[44,54]

➢ *Pioglitazone in NAFLD/NASH: Clinical Evidence*

The pivotal PIVENS trial (Sanyal et al., 2010) demonstrated that pioglitazone 30 mg daily for 96 weeks improved the NAFLD Activity Score (NAS) compared to placebo in non-diabetic patients with biopsy-proven NASH, with significant reductions in hepatic steatosis and inflammation.[5,51]

Cusi et al. (2016) subsequently demonstrated that pioglitazone 45 mg daily for 18 months resulted in NASH resolution in 51% of patients with T2DM, compared to 31% in the placebo group. This landmark trial also showed significant reductions in hepatic FFA delivery, de novo lipogenesis, and adipose tissue insulin resistance (Adipo-IR).[44,54,62]

A systematic review and meta-analysis of 15 randomized controlled trials (Pioglitazone on NASH, 2022) confirmed that pioglitazone significantly improves insulin and glucose parameters, increases lipid storage in subcutaneous adipose tissue, increases adiponectin, and reduces hepatic lipotoxicity.[17,52]

➢ *Mechanisms of Hepatic Lipid Reduction*

The hepatic lipid-lowering effects of pioglitazone operate through several complementary mechanisms: (1) redistribution of fat storage from visceral/hepatic to subcutaneous depots, reducing portal FFA delivery to the liver; (2) AMPK-mediated suppression of hepatic SREBP-1c and downstream lipogenic gene expression; (3) PPARα co-activation enhancing mitochondrial β-oxidation; and (4) adiponectin-driven improvement in hepatic insulin sensitivity, reducing the hyperinsulinemia that promotes lipogenesis.[15,17,18,34,62]

Mechanistic studies using magnetic resonance spectroscopy and imaging (MRS/MRI) in NASH patients have revealed that pioglitazone-induced improvement in liver histology (steatohepatitis activity) is strongly linked to increases in plasma adiponectin and decreases in the visceral-to-subcutaneous fat ratio (VF/SC), rather than overall weight change.[18] This finding highlights adipose tissue remodeling — not mere lipid lowering — as the key therapeutic target.[18,64]

➢ *Complex Hepatic Effects: A Dual Perspective*

Gene expression studies in preclinical models (KKAy obese diabetic mice) reveal a potentially paradoxical finding: pioglitazone-stimulated hepatic PPARγ hyperactivity may upregulate adipocyte-specific lipogenesis genes (FSP27/CIDEC, ap2, CD36, LPL, FATP-1), worsening microvesicular hepatic steatosis in genetically obese models while simultaneously reducing plasma triglycerides and FFA.[6,8,13] This divergence between plasma and hepatic lipid effects underscores the tissue-specific complexity of PPARγ activation and the importance of clinical trial data over animal model extrapolation for therapeutic decisions.[12,15]

➢ *Molecular Targets of Pioglitazone in Lipid Metabolism*

The lipid-modifying effects of pioglitazone are mediated through a complex network of molecular targets spanning multiple tissues. Table 3 provides a comprehensive overview of the key molecular targets, their tissue localization, the effect of pioglitazone on their expression or activity, and the resulting lipid metabolic consequences. [6,8,9,11,13,20,34]

Table 3 Molecular Targets of Pioglitazone in Lipid Metabolism

Molecular Target / Gene	Tissue / Compartment	Effect of Pioglitazone	Lipid Metabolic Consequence
PPARγ (nuclear receptor)	Adipose, liver, macrophage	Direct agonist activation	Master regulator of adipogenesis and lipid storage

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26may1804

SREBP-1c	Liver, adipose	Downregulation	↓De novo lipogenesis; ↓hepatic TG synthesis
Lipoprotein Lipase (LPL)	Adipose, muscle, heart	Upregulation	↑TG hydrolysis; ↓plasma TG; ↑FFA uptake
ApoC-III	Liver	Downregulation	↑LPL-mediated TG clearance; ↓VLDL-TG
ApoA-I	Liver (HepG2)	Upregulation via PPRE	↑HDL-C production and reverse cholesterol transport
CD36 / FAT	Adipose, muscle, liver	Upregulation	↑FFA uptake into adipose (trapping); ↓plasma FFA
FATP-1 (fatty acid transporter)	Adipose	Upregulation	Enhanced FFA sequestration in subcutaneous fat
HSL (hormone-sensitive lipase)	Adipose	Downregulation	↓Lipolysis; ↓FFA release to circulation
ATGL (adipose TG lipase)	Adipose	Suppressed context-dependently	↓TG hydrolysis in adipose; promotes fat storage
Adiponectin (AdipoQ)	Adipocytes	Marked upregulation	↑AMPK in liver/muscle; ↑β-oxidation; ↓gluconeogenesis
CPT-1a (carnitine palmitoyltransferase)	Liver, muscle	Context-dependent (↓in liver; ↑via adiponectin)	Modulates mitochondrial fatty acid oxidation
LDL-R (LDL receptor)	Liver	Variable; possible suppression	Altered LDL-C clearance; contributes to cholesterol changes
SR-BI (scavenger receptor B-I)	Liver	Possible downregulation	May reduce hepatic HDL-C uptake; raises plasma HDL
FSP27 (CIDEC)	Adipose	Marked upregulation (4.5-fold)	Promotes lipid droplet size; ↑TG storage in adipocytes
PPARα	Liver, heart	Indirect activation via adiponectin	↑Mitochondrial β-oxidation; ↓hepatic TG

➢ *Cardiovascular Implications of Pioglitazone-Mediated Lipid Modulation*

- *Anti-Atherogenic Lipid Profile*

The combined lipid effects of pioglitazone — reduced triglycerides, elevated HDL-C, shift from atherogenic small-dense LDL to large buoyant LDL, and reduced FFA — constitute a distinctly anti-atherogenic lipid profile. Favorable changes in the TG/HDL ratio have been correlated with delayed coronary atherosclerosis progression in clinical imaging studies.[26] In the PERISCOPE trial, which employed intravascular ultrasound to quantify coronary atheroma volume, pioglitazone significantly reduced atheroma progression compared to glimepiride over 18 months, despite similar glycemic control.[3]

- *Cardiovascular Outcomes: Clinical Trial Evidence*

The PROactive trial (n=5,238, 34.5 months) demonstrated that pioglitazone-treated patients with T2DM and established cardiovascular disease had a significant 16% reduction in the principal secondary composite endpoint (all-cause mortality, non-fatal MI, and stroke) compared to placebo, with concurrent improvements in HDL-C and TG.[2]

The Insulin Resistance Intervention after Stroke (IRIS) trial demonstrated that pioglitazone reduced the composite risk of stroke or myocardial infarction by 24% (HR 0.76, 95% CI 0.62–0.93) in patients with insulin resistance following recent ischemic stroke — a population without established T2DM.[4] These cardiovascular benefits are believed to result from the combined effects of improved insulin sensitivity, anti-atherogenic lipid modifications, and direct pleiotropic anti-inflammatory effects on vascular endothelium, smooth muscle cells, and macrophages.[24,28,30]

It is important to note that pioglitazone's cardiovascular benefits are class-specific and not generalizable to all TZDs. Rosiglitazone, the other commercially available TZD, has been associated with an increased risk of myocardial infarction in meta-analyses, leading to regulatory restrictions in Europe and a Black Box Warning in the United States.[23,25] This contrast further highlights the unique pharmacological properties of pioglitazone conferred by its dual PPARα/γ activity.[8,11]

➢ *Adipose Tissue Redistribution and Obesity*

- *Visceral vs. Subcutaneous Adipose Remodeling*

A pivotal mechanism through which pioglitazone improves lipid metabolism is through preferential redistribution of adipose tissue — specifically, reduction of visceral adipose tissue (VAT) and relative increase in subcutaneous adipose tissue (SAT). Visceral adipose tissue is metabolically hyperactive, characterized by elevated lipolysis, pro-inflammatory cytokine secretion, and high portal FFA delivery. Reduction of VAT is therefore a critical target in metabolic syndrome therapy.[25,64,65]

Studies using CT and MRI-based fat quantification demonstrate that pioglitazone significantly reduces VAT while subcutaneous fat may slightly increase — a phenomenon explained by PPARγ-driven differentiation of

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26may1804

pre-adipocytes in subcutaneous depots (adipogenesis) and redistribution of lipid storage from visceral to peripheral adipose tissue.[18,64] This redistribution pattern effectively reduces portal FFA delivery to the liver, improving hepatic lipid homeostasis and insulin sensitivity simultaneously.[18]

- *Weight Gain: Mechanisms and Clinical Context*

Body weight gain of 2–4 kg is a well-recognized and frequently cited adverse effect of pioglitazone, contributing to its declining use despite substantial metabolic benefits. Weight gain results from two distinct mechanisms: (1) expansion of adipose tissue mass, driven by PPARγ-induced adipogenesis; and (2) fluid retention due to renal collecting duct sodium reabsorption via PPARγ-mediated ENaC upregulation.[24,28] Importantly, however, the weight gained on pioglitazone is predominantly subcutaneous fat, whereas the metabolically harmful visceral fat is reduced — a favorable body composition change that paradoxically improves metabolic parameters despite increased total body weight.[18,64]

Combining pioglitazone with dietary caloric restriction (portion control) has been shown to attenuate weight gain while preserving glycemic and lipid benefits. In one study, the pioglitazone + portion control group demonstrated a weight loss of 2.59 kg versus weight gain of 2.15 kg in the pioglitazone + standard diet group, with greater reductions in waist circumference and visceral fat.[7,64]

VII. SAFETY PROFILE AND ADVERSE EFFECTS

➢ *Overview*

Despite its favorable metabolic and lipid-modifying profile, pioglitazone carries a well-characterized spectrum of adverse effects that require careful patient selection and monitoring. Key safety concerns include weight gain, peripheral edema, congestive heart failure exacerbation, bone fractures, potential bladder cancer risk, dilutional anemia, and rare hepatotoxicity. [23,24,25,26]

Table 4 Adverse Effects of Pioglitazone: Mechanisms, Incidence, and Management

Adverse Effect	Incidence	Severity	Mechanism	Management Strategy
Weight Gain	5–10% of BW	Moderate	Adipose differentiation & expansion; fluid retention	Caloric restriction; low-dose regimens
Peripheral Edema	4.8–15%	Mild-Moderate	Renal Na+ retention via ENaC in collecting duct	Dose reduction; diuretics if needed
Heart Failure (exacerbation)	Increased risk	Serious	Volume expansion; NOT direct myocardial toxicity	Contraindicated in NYHA Class III-IV HF
Bone Fractures	Increased in women	Moderate	↓Osteoblast differentiation; PPARγ osteoblast/adipocyte shift	Calcium/Vit D; DXA monitoring
Bladder Cancer	Possibly small ↑	Potentially serious	Mechanism unclear; PPARγ role in carcinogenesis debated	Avoid in bladder cancer history; regular screening
Dilutional Anemia	Uncommon	Mild	Plasma volume expansion	Monitor Hgb; usually self-limiting
Hepatotoxicity	Rare	Serious (rare)	Differs from troglitazone; mechanism unclear	Baseline LFTs; monitor if symptomatic
Hypoglycemia	Uncommon (alone)	Mild-Moderate	Risk increases with insulin/SU combination	Dose adjustment of concomitant agents

➢ *Bladder Cancer: Re-evaluation of Risk*

Concern about bladder cancer was initially raised by interim analyses of the PROactive trial, which demonstrated a higher incidence of bladder cancer in pioglitazone-treated patients. Subsequent epidemiological studies yielded conflicting results. However, a recent systematic review and meta-analysis of all available clinical trial data found no statistically significant increase in cancer incidence with pioglitazone treatment. [23,25,26,29] Current guidance recommends avoiding pioglitazone in patients with active bladder cancer or uninvestigated hematuria, while regular urological screening is advisable for long-term users.[23]

➢ *Heart Failure: Risk Context and Management*

Pioglitazone does not exert direct negative inotropic effects on myocardial function; rather, its association with heart failure is attributable to volume expansion from fluid retention.[24,28] The drug is contraindicated in patients with NYHA Class III-IV heart failure. In patients with mild (Class I-II) heart failure and metabolic syndrome, the risk-benefit ratio must be carefully individualized. Notably, data from the PROactive trial and subsequent analyses suggest pioglitazone does not increase atherosclerotic cardiovascular events and may reduce ischemic events — a reassuring finding that distinguishes pioglitazone favorably from rosiglitazone. [2,25,30]

➢ *Emerging Developments and Future Directions*

- *PXL065: Deuterium-Stabilized R-Pioglitazone*

A major limitation of conventional pioglitazone is its metabolism to the S-pioglitazone enantiomer, which lacks metabolic efficacy. PXL065 (deuterium-stabilized R-pioglitazone) represents a novel formulation designed to stabilize the pharmacologically active R-enantiomer, enabling lower effective doses while maintaining lipid and metabolic benefits, and potentially reducing adverse effects including weight gain and fluid retention.[22,15]

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26may1804

The DESTINY-1 Phase II trial evaluated PXL065 (7.5–22.5 mg) in NASH patients. All active dose groups met the primary endpoint of ≥30% reduction in liver fat content (LFC). Additionally, PIIINP (fibrosis marker) and NAFLD fibrosis score showed favorable trends. Critically, adiponectin increased by 114% at the 22.5 mg dose without dose-dependent effects on body weight or significant peripheral edema.[22] These findings suggest PXL065 may offer a superior benefit-risk profile compared to conventional racemic pioglitazone.[15,22]

- *Dual PPARα/γ Agonists and Saroglitazar*

The distinct mechanisms by which PPARα and PPARγ activation complement each other in lipid metabolism have spurred the development of balanced dual PPARα/γ agonists. Saroglitazar, approved in India for diabetic dyslipidemia and NAFLD, demonstrates potent TG-lowering (45–60%), HDL-C elevation, and hepatic lipid improvement while carrying a reduced weight gain and fluid retention burden compared to pioglitazone.[59] These agents represent the therapeutic evolution of the pioglitazone concept, preserving lipid benefits while ameliorating adverse effects.[59]

- *Combination Therapy Strategies*

Pioglitazone has been extensively evaluated in combination regimens. The triple-combination of pioglitazone/exenatide/metformin (EDICT trial) demonstrated reductions in hepatic fibrosis and steatosis beyond those seen with individual agents, suggesting synergistic effects on hepatic lipid metabolism through complementary mechanisms targeting insulin resistance, glucagonlike peptide-1 signaling, and PPARγ activation simultaneously.[9]

Combination with statins in patients with NAFLD/NASH has been explored, with preliminary evidence suggesting additive effects on hepatic steatosis reduction, though formal RCT evidence for this combination remains limited.[3,55] Optimization of pioglitazone combination strategies represents an important area for future clinical investigation, particularly in the context of the recently expanded NAFLD therapeutic landscape.[52,57]

VIII. CLINICAL CONSIDERATIONS AND PATIENT SELECTION

➢ *Optimal Patient Profile*

Based on the comprehensive evidence reviewed, pioglitazone's lipid-modifying and metabolic benefits are most pronounced in patients with: established insulin resistance or T2DM with atherogenic dyslipidemia (elevated TG + low HDL-C); biopsy-proven or clinically suspected NAFLD/NASH; history of ischemic stroke or TIA with insulin resistance; and prediabetes with metabolic syndrome and high cardiovascular risk.[1,4,5,31,44]

➢ *Contraindications and Precautions*

Absolute contraindications include symptomatic congestive heart failure (NYHA Class III-IV), known active bladder cancer, and hypersensitivity to pioglitazone. Relative contraindications include NYHA Class I-II heart failure (requires careful monitoring), history of bladder cancer, severe osteoporosis particularly in postmenopausal women, and patients at high fracture risk.[23,24]

➢ *Monitoring Parameters*

Recommended monitoring during pioglitazone therapy includes: fasting lipid panel (TG, HDL-C, LDL-C) at baseline, 3 months, and annually; liver function tests (ALT, AST) at baseline and periodically; body weight and edema assessment at each visit; hemoglobin/hematocrit for dilutional anemia; and DEXA scanning for bone mineral density in at-risk patients. Bladder cancer surveillance (urine cytology, urinalysis) is recommended for long-term users (>2 years).[23,24,25]

IX. SYNTHESIS AND DISCUSSION

Pioglitazone occupies a unique niche in the pharmacotherapy of metabolic disease by virtue of its pleiotropic, mechanism-based lipid-modifying effects that address the full spectrum of atherogenic dyslipidemia characteristic of metabolic syndrome and obesity. Unlike statins, which primarily reduce LDL-C through HMG-CoA reductase inhibition, or fibrates, which primarily reduce TG via PPARα activation, pioglitazone acts as a 'metabolic reprogrammer' — redistributing adipose tissue, reorienting FFA flux, restoring adipokine balance, and improving the fundamental insulin-resistant metabolic state that drives lipid abnormalities.[1,8,9,15]

The evidence strongly supports pioglitazone's ability to simultaneously: reduce plasma triglycerides (10–30%), elevate HDL-cholesterol (10–15%), shift LDL particle distribution toward the less atherogenic large-buoyant subtype, reduce small-dense LDL particles by up to 18%, suppress circulating FFA (15–25%), dramatically increase adiponectin (50–111%), reduce CRP by up to 31%, and improve hepatic lipid content in NAFLD/NASH. This metabolic profile is unmatched by any other single pharmacological agent in the T2DM armamentarium.[2,3,4,5,7,9,22,44]

The adverse effect profile — particularly weight gain, edema, heart failure risk, and bone fractures — has undeniably limited pioglitazone's clinical utilization, particularly in the era of GLP-1 receptor agonists and SGLT-2 inhibitors, which offer weight loss and cardiovascular benefits. However, these newer agents do not replicate pioglitazone's effects on hepatic steatosis resolution, adiponectin elevation, or qualitative LDL improvement, suggesting complementary rather than competitive therapeutic roles.[21,23,25]

The emergence of deuterium-stabilized R-pioglitazone (PXL065) and balanced dual PPARα/γ agonists offers the prospect of preserving the lipid and hepatic metabolic benefits of pioglitazone while mitigating its adverse effects — potentially revitalizing this pharmacological class for broader clinical application in metabolic syndrome.[22,59]

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26may1804

X. CONCLUSIONS

Pioglitazone mediates comprehensive, mechanism-based modulation of lipid metabolism in obesity and metabolic syndrome through its PPARγ agonist activity and associated molecular cascades. Its lipid effects encompass: (1) triglyceride reduction via LPL upregulation and ApoC-III suppression; (2) HDL-cholesterol elevation via ApoA-I upregulation and enhanced reverse cholesterol transport; (3) qualitative improvement in LDL particle size; (4) FFA reduction through adipose lipolysis suppression and visceral-to-subcutaneous fat redistribution; (5) profound adiponectin elevation and resultant downstream metabolic benefits; and (6) hepatic lipid improvement with NAFLD/NASH resolution in clinical trials.[1-65]

These effects collectively produce a distinctly anti-atherogenic lipid phenotype with proven cardiovascular benefits in high-risk populations (PROactive, PERISCOPE, IRIS trials). Adverse effects require careful patient selection, but the emerging PXL065 formulation and combination therapy strategies may extend pioglitazone's therapeutic utility while improving tolerability. In the context of the metabolic syndrome epidemic, pioglitazone's unique lipid-modifying profile represents an underutilized therapeutic resource warranting re-evaluation in precision medicine approaches targeting specific metabolic phenotypes.[4,22,26,29]

REFERENCES

[1]. Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr Diab Rep. 2019;19(12):151. doi:10.1007/s11892-019-1270-y

[2]. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study. Lancet. 2005;366(9493):1279-1289.

[3]. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. JAMA. 2008;299(13):1561-1573.

[4]. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321-1331.

[5]. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685.

[6]. Peng XE, Hu YL, Liu C, Xu ML. Effects and potential mechanisms of pioglitazone on lipid metabolism in obese diabetic KKAy mice. PPAR Res. 2014;2014:538183.

[7]. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006;26(2):407-413.

[8]. Derosa G, Cicero AF. Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Curr Drug Targets. 2008;9(6):480-489.

[9]. Bell DS. In praise of pioglitazone: an economically efficacious therapy for type 2 diabetes and other manifestations of the metabolic syndrome. Diabetes Obes Metab. 2023;25(8):2070-2080.

[10]. Tavintharan S, Ong CN, Tay EL, Gu P, Fan HY, Tai ES. Effects of pioglitazone on asymmetric dimethylarginine and components of the metabolic syndrome in nondiabetic patients (EPICAMP study). Cardiovasc Diabetol. 2013;12:53.

[11]. Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30(10):2458-2464.

[12]. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996;37(5):907-925.

[13]. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-435.

[14]. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45(12):1661-1669.

[15]. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106-1118.

[16]. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000;49(10):497-505.

[17]. Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis. 2009;205(1):1-8.

[18]. Zhang F, Lavan BE, Gregoire FM. Selective modulators of PPAR-gamma activity: molecular aspects related to obesity and side-effects. PPAR Res. 2007;2007:32696.

[19]. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998;47(4):507-514.

[20]. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem. 2008;77:289-312.

[21]. Tan GD, Fielding BA, Currie JM, et al. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia. 2005;48(1):83-95.

[22]. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89(2):463-478.

[23]. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711-725.

[24]. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679-689.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26may1804

[25]. Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb. 2011;18(8):629-639.
[26]. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433-438.
[27]. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059-1062.
[28]. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-359.
[29]. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415-1428.
[30]. Zimmet P, Alberti KG, Serrano Ríos M. A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results. Rev Esp Cardiol. 2005;58(12):1371-1375.
[31]. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104-1115.
[32]. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930-1935.
[33]. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784-1792.
[34]. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8(11):1288-1295.
[35]. Moreno-Aliaga MJ, Lorente-Cebrián S, Martínez JA. Regulation of adipokine secretion by n-3 fatty acids. Proc Nutr Soc. 2010;69(3):324-332.
[36]. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50(9):2094-2099.
[37]. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270(45):26746-26749.
[38]. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996;37(4):693-707.
[39]. Yagyu H, Iida K, Imamura K, et al. Overexpression of lipoprotein lipase in osteoblasts increases cortical bone mass in mice. FASEB J. 2012;26(7):3179-3185.
[40]. Staels B, Auwerx J. Perturbation of developmental programmes by fibrates and thiazolidinediones: species differences and potential relevance to humans. FEBS Lett. 1998;438(1-2):19-24.
[41]. Berthou L, Duverger N, Emmanuel F, et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest. 1996;97(11):2408-2416.
[42]. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686-690.
[43]. Pappachan JM, Babu MS, Krishnagopal P, Jayaraman S. Low-dose pioglitazone improves non-alcoholic fatty liver disease in type 2 diabetes. Sci Rep. 2022;12(1):1234.
[44]. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with NASH and prediabetes or T2DM. Ann Intern Med. 2016;165(5):305-315.
[45]. Leavens KF, McKnight RA, Crabtree GS, Bhatt DL, Bhattacharya SK. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metab. 2009;10(5):405-418.
[46]. Hotamisligil GS. Inflammation and metabolic disease. Nature. 2006;444(7121):860-867.
[47]. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793-1801.
[48]. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104(4):503-516.
[49]. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-1695.
[50]. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537-2564.
[51]. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14(2):72-81.
[52]. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357.
[53]. Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care. 2017;40(3):419-430.
[54]. Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with NASH and prediabetes or T2DM: a randomized trial. Ann Intern Med. 2016;165:305-315.
[55]. Rombouts K, Niki T, Greenwel P, et al. Atorvastatin inhibits activation of hepatic stellate cells. Lab Invest. 2003;83(6):863-873.
[56]. Beraza N, Marqués JM, Martínez-Ansó E, et al. Interplay between liver growth, apoptosis and autophagy in a murine model of chronic liver injury. J Hepatol. 2009;51(2):361-371.
[57]. Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis. N Engl J Med. 2018;379(22):2063-2074.
[58]. Loomba R, Sanyal AJ, Kowdley KV, et al. Randomized, controlled trial of the FXR agonist

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/26may1804

cilofexor in noncirrhotic patients with NASH. Clin Gastroenterol Hepatol. 2020;18(12):2792-2802.
[59]. Jain MR, Giri SR, Bhoi B, et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int. 2018;38(6):1084-1094.
[60]. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643-654.
[61]. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121-129.
[62]. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004;89(1):200-206.
[63]. Cali AM, Bonadonna RC, Trombetta M, Weiss R, Caprio S. Metabolic abnormalities underlying the different prediabetic phenotypes in obese adolescents. J Clin Endocrinol Metab. 2008;93(5):1767-1773.
[64]. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87(6):2784-2791.
[65]. Miyazaki Y, Glass L, Triplitt C, et al. Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab. 2002;283(6):E1135-E1143.